Acceleration of the effect of selected antidepressants drugs in major depression by 5-HT(1A) antagonists

Trends in Neurosciences

Volumn 19, Issue 9, 1996, Pages 378-383

  Artigas, Francesc ^a   Romero, Luz ^a   De Montigny, Claude ^b   Blier, Pierre ^b  

^a INST D INVESTIGACIONS B   (Spain)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

8 [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] 8 AZASPIRO[4.5]DECANE 7,9 DIONE; ANTIDEPRESSANT AGENT; AUTORECEPTOR; CITALOPRAM; FLUOXETINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PAROXETINE; PINDOLOL; PROPRANOLOL; SEROTONIN 1A RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TERTATOLOL;

ANIMAL EXPERIMENT; CORPUS STRIATUM; DEPRESSION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAPHE NUCLEUS; RAT; REVIEW; SEROTONIN RELEASE; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030247182     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-2236(96)10037-0     Document Type: Article

References (66)

1. 1 Caldecott-Hazard, S. et al. (1991) Synapse 8, 185-211
2. 2 National Advisory Mental Health Council (1993) Am. J. Psychiatry 150, 1447-1465
3. 3 Cusack, B., Nelson, A. and Richelson, E. (1994) Psychopharmacology 114, 559-565
4. 4 Elkin, I. et al. (1989) Arch. Gen. Psychiatry 46, 971-983
5. 5 Baker, G.B. and Greenshaw, A.J. (1989) Cell. Mol. Neurobiol. 9, 1-44
6. 6 Caldecott-Hazard, S. et al. (1991) Synapse 9, 251-301
7. 7 Blier, P. and De Montigny, C. (1994) Trends Pharmacol. Sci. 15, 220-226
8. 8 Vetulani, J. and Sulser, F. (1975) Nature 257, 495-496
9. 9 Peroutka, S.J. and Snyder, S.H. (1980) Science 210, 88-90
10. 10 Dechant, K.L. and Clissold, S.P. (1991) Drugs 41, 225-253
11. 11 Hyttel, J., Overo, K.F. and Arnt, J. (1984) Psychopharmacology 83, 20-27
12. 12 Barden, N., Reul, J.M.H.M. and Holsboer, F. (1995) Trends Neurosci. 18, 6-11
13. 13 Shopsin, B. et al. (1975) Psychopharmacol. Commun. 1, 239-249
14. 14 Delgado, P.L. et al. (1990) Arch. Gen. Psychiatry 47, 411-418
15. 15 Sharp, T. et al. (1991) Neuropharmacology 30, 977-984
16. 16 Sharp, T., Bramwell, S.R. and Grahame-Smith, D.G. (1992) Life Sci. 50, 1215-1223
17. 17 De Montigny, C. et al. (1983) Arch. Gen. Psychiatry 40, 1327-1334
18. 18 Ayuso Gutiérrez, J.L. and López-Ibor, J.J. (1971) Int. Pharmacopsychiatry 7, 92-97
19. 19 Aghajanian, G.K., Graham, A.W. and Sheard, M.H. (1970) Science 169, 1100-1102
20. 20 Quinaux, N., Scuvée-Moreau, J. and Dresse, A. (1982) Naunyn-Schmiedeberg's Arch. Pharmacol. 319, 66-70
21. 21 Blier, P. and De Montigny, C. (1985) Neuroscience 16, 949-955
22. 22 Blier, P., De Montigny, C. and Chaput, Y. (1987) J. Clin. Psychopharmacol. 7, 24S-35S
23. 23 Blier, P., Chaput, Y. and De Montigny, C. (1988) Naunyn-Schmiedeberg's Arch. Pharmacol. 337, 246-254
24. 24 Blier, P. and Bouchard, C. (1994) Br. J. Pharmacol. 113, 485-495
25. 25 Sharp, T., Bramwell, S.R. and Grahame-Smith, D.G. (1990) Neuroscience 39, 629-637
26. 26 Adell, A. and Artigas, F. (1991) Naunyn-Schmiedeberg's Arch. Pharmacol. 343, 237-244
27. 27 Bel, N. and Artigas, F. (1992) Eur. J. Pharmacol. 229, 101-103
28. 28 Invernizzi, R., Belli, S. and Samanin, R. (1992) Brain Res. 584, 322-324
29. 29 Celada, P. and Artigas, F. (1993) Naunyn-Schmiedeberg's Arch. Pharmacol. 347, 583-590
30. 30 Pazos, A. and Palacios, J.M. (1985) Brain Res. 346, 205-230
31. 31 Sotelo, C. et al. (1990) Eur. J. Neurosci. 2, 1144-1154
32. 32 Sprouse, J.S. and Aghajanian, G.K. (1987) Synapse 1, 3-9
33. 33 Bel, N. and Artigas, F. (1993) Synapse 15, 243-245
34. 34 Ferrer, A. and Artigas, F. (1994) Eur. J. Pharmacol. 263, 227-234
35. 35 Kreiss, D.S. and Lucki, I. (1995) J. Pharmacol. Exp. Ther. 274, 866-876
36. 36 Invernizzi, R., Bramante, M. and Samanin, R. (1994) Eur. J. Pharmacol. 260, 243-246
37. 37 Rutter, J.J., Gimdlah, C. and Auerbach, S.B. (1994) Neurosci. Lett. 171, 183-186
38. 38 Bel, N. and Artigas, F. J. Neurochem. (in press)
39. 39 Artigas, F. (1993) Trends Pharmacol. Sci. 14, 262
40. 40 Hrdina, P.D. et al. (1990) J. Pharmacol. Exp. Ther. 252, 410-418
41. 41 Cortés, R. et al. (1988) Neuroscience 27, 473-496
42. 42 Héry, F., Faudon, M. and Ternaux, J.P. (1982) Brain Res. Bull. 8, 123-129
43. 43 Adell, A., Carceller, A. and Artigas, F. (1993) J. Neurochem. 60, 1673-1681
44. 44 Oleskevich, S. et al. (1991) Neuroscience 42, 777-791
45. 45 Romero, L., Celada, P. and Artigas, F. (1994) Eur. J. Pharmacol. 265, 103-106
46. 46 Innis, R.B. and Aghajanian, G.K. (1987) Eur. J. Pharmacol. 143, 195-204
47. 47 Imai, H., Steindler, D.A. and Kitai, S.T. (1986) J. Comp. Neurol. 243, 363-380
48. 48 Romero, L. et al. Neuropsychopharmacology (in press)
49. 49 Gartside, S.E. et al. (1995) Br. J. Pharmacol. 115, 1064-1070
50. 50 Hjorth, S. (1993) J. Neurochem. 60, 776-779
51. 51 Bruinvels, A.T. et al. (1992) Naunyn-Schmiedeberg's Arch. Pharmacol. 346, 243-248
52. 52 Palacios, J.M., Probst, A. and Cortés, R. (1983) Brain Res. 274, 150-155
53. 53 Chaput, Y., De Montigny, C. and Blier, P. (1991) Neuropsychopharmacology 5, 219-229
54. 54 Luscombe, G.P. et al. (1993) Br. J. Pharmacol. 108, 669-677
55. 55 Radja, F. et al. (1992) J. Neurochem. 58, 1338-1346
56. 56 Meller, E., Goldstein, M. and Bohmaker, K. (1990) Mol. Pharmacol. 37, 231-237
57. 57 Blier, P., Lista, A. and De Montigny, C. (1993) J. Pharmacol. Exp. Ther. 265, 7-15
58. 58 Chaput, Y. and De Montigny, C. (1988) J. Pharmacol. Exp. Ther. 246, 359-376
59. 59 Albert, P.R. et al. (1990) J. Biol. Chem. 265, 5825-5832
60. 60 Hoyer, D. and Schoeffter, P. (1991) J. Recept. Res. 11, 197-214
61. 61 Aulakh, C.S. et al. (1988) Eur. J. Pharmacol. 146, 253-259
62. 62 Middlemiss, D.N., Neill, J. and Tricklebank, M.D. (1985) Br. J. Pharmacol. 85, 25
63. 63 Artigas, F., Pérez, V. and Alvarez, E. (1994) Arch. Gen. Psychiatry 51, 248-251
64. 64 Blier, P. and Bergeron, R. (1995) J. Clin. Psychopharmacol. 15, 217-222
65. 65 Avorn, J., Everitt, D.E. and Weiss, S. (1986) J. Am. Med. Assoc. 255, 357-360
66. 66 Bergeron, R., De Montigny, C. and Blier, P. (1995) Psychopharmacol. Bull. 31, 555